Arginine--tRNA Ligase, Cytoplasmic (RARS1) Antibody
REQUEST MORE INFO
Catalogue No: abx004821
Price:
US$348.00
(Size: 60 µl)
Orders to United States ship from United States
Add to Cart
Buy It Now
GET A QUOTE
Documents
Datasheet SDS
Arginine--tRNA Ligase, Cytoplasmic (RARS1) Antibody is a Rabbit Polyclonal antibody against RARS. Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Arginyl-tRNA synthetase belongs to the class-I aminoacyl-tRNA synthetase family.
Research Articles on Arginine--tRNA Ligase, Cytoplasmic (RARS1)
| Target | Arginine--tRNA Ligase, Cytoplasmic (RARS1) |
| Research Area | Enzymes and Kinases |
| Clonality | Polyclonal |
| Reactivity | Human, Mouse, Rat |
| Tested Applications | IHC, IF/ICC |
| Host | Rabbit |
| Recommended dilutions | IHC-P: 1/50 - 1/200, IF/ICC: 1/10 - 1/100. Not tested in IHC-F. Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Immunogen | Recombinant fusion protein corresponding to human RARS |
| Isotype | IgG |
| Form | Liquid |
| Purification | Purified by affinity chromatography. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Shelf Life | 12 months. |
| UniProt Primary AC | P54136 (UniProt, ExPASy) |
| UniProt Secondary AC | B2RBS9, Q53GY4, Q9BWA1 |
| UniProt Entry Name | SYRC_HUMAN |
| Gene Symbol | RARS1 |
| GeneID | 5917 |
| NCBI Accession | NP_002878.2 |
| HGNC | 9870 |
| KEGG | hsa:5917 |
| Ensembl | ENSG00000113643 |
| String | 9606.ENSP00000231572 |
| Buffer | PBS, pH 7.3, containing 0.02% sodium azide, 50% glycerol. |
| Concentration | 1 mg/ml |
| Availability | Shipped within 5-10 working days. |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |








